ARGX Earnings Date: Feb 25, 2027 (Estimated) — argenx SE
NASDAQ · Healthcare · Biotechnology
Updated
When is ARGX's next earnings date?
argenx SE (ARGX) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 1:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $8.69 on revenue of $1.79B.
How did ARGX do in its last earnings report?
In its most recent report on Jul 30, 2026, argenx SE posted EPS of $7.80 versus the $7.44 estimate, a beat. Revenue was $2.82B against a $1.66B estimate. The stock's 1-day post-earnings move was -3.3%.
How much does ARGX stock move after earnings?
ARGX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 5.8% (up or down) in the day after earnings.
About argenx SE
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
🤖 AI Earnings Analysis
ARGX trades at 29.6× earnings with a 31.1% profit margin; no recent news, guidance revisions, or earnings-surprise data were provided to identify a stronger catalyst.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | 7.44 | 7.80 | — | $2.82B | ✅ Beat | -3.26% | -1.66% | +19.98% | |
| 2026-07-23 | Q2 2026 | 5.56 | 7.32 | +31.65% | $1.54B | ✅ Beat | +8.56% | +3.62% | +21.89% |
| 2026-05-07 | Q1 2026 | 4.39 | 5.52 | +25.74% | $1.31B | ✅ Beat | -2.51% | -0.60% | +10.37% |
| 2026-02-26 | Q4 2025 | 5.64 | 8.02 | +42.20% | $1.32B | ✅ Beat | -5.56% | -8.25% | -15.19% |
| 2025-10-30 | Q3 2025 | 3.88 | 5.18 | +33.51% | $1.15B | ✅ Beat | -0.20% | +1.26% | +10.95% |
| 2025-07-31 | Q2 2025 | 2.73 | 3.74 | +37.00% | $967.2M | ✅ Beat | +11.93% | +12.40% | +17.56% |
| 2025-05-08 | Q1 2025 | 1.97 | 2.58 | +30.96% | $807.3M | ✅ Beat | -8.64% | -14.55% | -5.94% |
| 2025-02-27 | Q4 2024 | 1.06 | 0.93 | -12.26% | $761.2M | ❌ Miss | — | — | — |
Showing last 8 quarters.
Revenue by segment & region
By region
Q4 FY23 · $688.5M total
| Segment | Share | Revenue | YoY | Q2 FY20 | Q2 FY21 | Q2 FY22 | Q2 FY23 |
|---|---|---|---|---|---|---|---|
| United States | 88.0% | $605.7M | — | — | — | $94.3M | $440.9M |
| EMEA | 7.3% | $50.0M | — | — | — | — | $22.8M |
| Japan | 4.8% | $32.8M | — | — | — | $1.5M | $23.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.